Sarepta surges on FDA's expanded use nod for company's Duchenne gene therapy
** Shares of Sarepta Therapeutics SRPT.O surged about 33% to a more than three-year high in early trade
** At current levels, nearly $4 bln was set to be added to company's market value
** Late on Thursday, U.S. FDA granted traditional approval for company's gene therapy, Elevidys, for patients with inherited progressive muscle-wasting disorder
** Agency's nod allows use in kids aged four-year and above who can walk, as well as an accelerated approval for those who cannot
** Elevidys could now be given to about 13,000 patients, nearly 90% of U.S. patients - BMO Capital Markets
** Analysts from different brokerages flagged manufacturing concerns and insurance coverage for newly added patients as limiting factors
** Shares of Catalent CTLT.N, contract manufacturer of Elevidys for SRPT, rise 3.3% to $56.60
** Thermo Fisher Scientific TMO.N, earlier added as a secondary manufacturer for SRPT's therapy, up 1.6% at $565.82
** Including session's gain, company stock up more than 68% YTD
Reporting by Pratik Jain in Bengaluru
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
